SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2013.
"We are very encouraged by the positive response from patients and physicians since BELVIQ became available in US pharmacies on June 11," said Jack Lief, Arena's President and Chief Executive Officer. "While it is still early in the launch, the progress made to date reinforces the significant opportunity we see for BELVIQ in the medical management of overweight and obese patients."
Recent Developments:BELVIQ US Launch
BELVIQ Rest of World
BELVIQ Additional Developments
Research & Development
Second Quarter 2013 Financial Results
Scheduled Conference Call and WebcastArena will host a conference call and webcast to provide a corporate update and report second quarter 2013 financial results today at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Second Quarter 2013 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Upcoming Conference ParticipationArena is planning to participate at upcoming investment and industry conferences, including:
About BELVIQ® (lorcaserin HCl) CIVBELVIQ (pronounced BEL-VEEK) is approved by the US Food and Drug Administration for chronic weight management, and is available by prescription in the United States. BELVIQ is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain. The exact mechanism of action is not known. For more information about BELVIQ, click here for the full Product Information or visit www.BELVIQ.com.
BELVIQ is indicated to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of:
Limitations of Use:
In clinical trials, the most common adverse reactions for patients without diabetes treated with BELVIQ were headache, dizziness, fatigue, nausea, dry mouth, and constipation. In patients with diabetes, the most common adverse reactions were hypoglycemia, headache, back pain, cough, and fatigue.
Arena has granted exclusive marketing and distribution rights to Eisai Inc. for most of North and South America, to Ildong Pharmaceutical Co., Ltd., for South Korea, and to CY Biotech Company Ltd. for Taiwan. Arena plans to enter into additional collaborations to commercialize BELVIQ outside of these territories.
About Arena PharmaceuticalsArena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, is approved in the United States and is under review for regulatory approval in additional territories. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.
Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, mechanism of action, regulatory review and approval, and potential of BELVIQ; opportunity provided by BELVIQ, including in the medical management of patients; research and development relating to BELVIQ, including in combination with phentermine and related plans; rights and obligations under the marketing and supply agreement with CYB; the therapeutic indication, safety and efficacy of APD811 and APD334 and related expectations; plans to enter into additional collaborations and related strategy; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on management's estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding Arena's estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contact: Arena Pharmaceuticals, Inc.
Media Contact: Russo PartnersCindy McGee, Vice President,
David Schull, PresidentInvestor Relations & Alliance Management
858.717.2310858.453.7200, ext. 1479 Arena Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations (In thousands, except per share data)Three months endedSix months endedJune 30,June 30,2013201220132012(unaudited)(unaudited)RevenuesNet product sales
$ 1,319$$ 1,319$Eisai collaborative revenue
9731,0291,7382,321Other collaborative revenue
1702928367 Total revenues
68,92721,97771,30024,166Operating Costs & ExpensesCost of product sales
58101,0540Cost of manufacturing services
1,0096522,6541,443Research & development
18,82814,07632,83628,546General & administrative
8,6035,21615,85411,571Amortization of acquired technology & other intangibles
01730349 Total operating costs & expenses
29,02120,11752,39841,909Interest & Other Income (Expense)Interest income
(1,778)(2,489)(3,565)(5,520)Gain (Loss) from valuation of derivative liabilities
2,142(16,770)6,001(19,145)Loss on extinguishment of debt
(186)(57)(154)30 Total interest & other income (expense), net
194(23,959)2,322(30,933)Net income (loss)
40,100(22,099)21,224(48,676)Deemed dividend related to beneficial conversion
feature of convertible preferred stock
000(2,824)Net income (loss) allocable to common stockholders
$40,100$(22,099)$21,224$(51,500)Net income (loss) per share allocable to common
(0.29)Shares used in calculating net income (loss) per share
allocable to common stockholders:Basic
224,528190,272224,551177,243Arena Pharmaceuticals, Inc.Condensed Consolidated Balance Sheet Data(In thousands)June 30, 2013December 31, 2012(unaudited)1Assets Cash & cash equivalents
$ 178,905$ 156,091 Accounts receivable
7,2456,058 Prepaid expenses & other current assets
3,1743,454 Land, property & equipment, net
73,89875,417 Acquired technology & other non-current assets
$ 277,954$ 261,206Liabilities & Stockholders' Equity Accounts payable & accrued liabilities
$ 16,932$ 10,210 Total deferred revenues
53,18362,735 Total derivative liabilities
9,04115,042 Total lease financing obligations & other long-term liabilities
73,85674,580 Total stockholders' equity
124,94298,639Total liabilities & stockholders' equity
$ 277,954$ 261,2061 The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.
|SOURCE Arena Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved